Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS Sprycel Leukemia Drug Approved | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

BMS Sprycel Leukemia Drug Approved

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb was granted accelerated approval by the FDA for Sprycel, an oral inhibitor of multiple tyrosine kinases for the treatment of adults in all phases of chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy, including Gleevec. The FDA also granted full approval of Sprycel for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) with resistance or intolerance to prior therapy. The company anticipates that the drug will be available within days nationwide.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters